580 related articles for article (PubMed ID: 11796404)
1. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.
Ribbens C; Martin y Porras M; Franchimont N; Kaiser MJ; Jaspar JM; Damas P; Houssiau FA; Malaise MG
Ann Rheum Dis; 2002 Feb; 61(2):161-6. PubMed ID: 11796404
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis.
Ichikawa Y; Yamada C; Horiki T; Hoshina Y; Uchiyama M
Clin Exp Rheumatol; 1998; 16(5):533-40. PubMed ID: 9779299
[TBL] [Abstract][Full Text] [Related]
4. Serum biochemistry in rheumatoid arthritis, seronegative arthropathies, osteoarthritis, SLE and normal subjects.
Sitton NG; Dixon JS; Bird HA; Wright V
Br J Rheumatol; 1987 Apr; 26(2):131-5. PubMed ID: 3828665
[TBL] [Abstract][Full Text] [Related]
5. Serum matrix metalloproteinase-3 in systemic sclerosis.
Jinnin M; Ihn H; Asano Y; Yamane K; Yazawa N; Tamaki K
Arch Dermatol Res; 2004 Jun; 296(1):25-9. PubMed ID: 15095096
[TBL] [Abstract][Full Text] [Related]
6. Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis.
Cunnane G; Fitzgerald O; Beeton C; Cawston TE; Bresnihan B
Arthritis Rheum; 2001 Oct; 44(10):2263-74. PubMed ID: 11665967
[TBL] [Abstract][Full Text] [Related]
7. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of cartilage oligomeric matrix protein are elevated in rheumatoid arthritis, but not in inflammatory rheumatic diseases such as psoriatic arthritis, reactive arthritis, Raynaud's syndrome, scleroderma, systemic lupus erythematosus, vasculitis and Sjögren's syndrome.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Arthritis Res Ther; 2004; 6(2):73-4. PubMed ID: 15059267
[No Abstract] [Full Text] [Related]
9. [Changes in blood calcium, phosphorus and alkaline phosphatase levels in rheumatoid polyarthritis and other types of inflammatory rheumatism].
Bontoux D; Alcalay M; Reboux JF; Thomas P; Joyeux F; Hofnung D
Rev Rhum Mal Osteoartic; 1979 Jun; 46(6):389-95. PubMed ID: 315611
[TBL] [Abstract][Full Text] [Related]
10. Erythrocyte sedimentation rate within rheumatic disease clinics.
Giacomello A; Quaratino CP; Zoppini A
J Rheumatol; 1997 Nov; 24(11):2263-5. PubMed ID: 9375897
[No Abstract] [Full Text] [Related]
11. Matrix metalloproteinases MMP-3 and MMP-1 levels in sera and synovial fluids in patients with rheumatoid arthritis and osteoarthritis.
Mahmoud RK; El-Ansary AK; El-Eishi HH; Kamal HM; El-Saeed NH
Ital J Biochem; 2005; 54(3-4):248-57. PubMed ID: 16688934
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor in patients with rheumatoid arthritis.
Harada M; Mitsuyama K; Yoshida H; Sakisaka S; Taniguchi E; Kawaguchi T; Ariyoshi M; Saiki T; Sakamoto M; Nagata K; Sata M; Matsuo K; Tanikawa K
Scand J Rheumatol; 1998; 27(5):377-80. PubMed ID: 9808403
[TBL] [Abstract][Full Text] [Related]
13. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
Goldbach-Mansky R; Lee JM; Hoxworth JM; Smith D; Duray P; Schumacher RH; Yarboro CH; Klippel J; Kleiner D; El-Gabalawy HS
Arthritis Res; 2000; 2(2):145-53. PubMed ID: 11062605
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis.
Posthumus MD; Limburg PC; Westra J; van Leeuwen MA; van Rijswijk MH
Clin Exp Rheumatol; 2003; 21(4):465-72. PubMed ID: 12942698
[TBL] [Abstract][Full Text] [Related]
15. [Thrombocytosis in progressive generalized sclerosis (scleroderma) and in other rheumatic diseases].
Valentini G; Chianese U; Tirri G; Giordano M
Z Rheumatol; 1978; 37(7-8):233-41. PubMed ID: 308747
[TBL] [Abstract][Full Text] [Related]
16. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis.
Yoshihara Y; Obata K; Fujimoto N; Yamashita K; Hayakawa T; Shimmei M
Arthritis Rheum; 1995 Jul; 38(7):969-75. PubMed ID: 7612046
[TBL] [Abstract][Full Text] [Related]
17. Serum nitrate and nitrite levels in patients with rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis.
Ersoy Y; Ozerol E; Baysal O; Temel I; MacWalter RS; Meral U; Altay ZE
Ann Rheum Dis; 2002 Jan; 61(1):76-8. PubMed ID: 11779766
[TBL] [Abstract][Full Text] [Related]
18. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
Green MJ; Gough AK; Devlin J; Smith J; Astin P; Taylor D; Emery P
Rheumatology (Oxford); 2003 Jan; 42(1):83-8. PubMed ID: 12509618
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis.
Kobayashi A; Naito S; Enomoto H; Shiomoi T; Kimura T; Obata K; Inoue K; Okada Y
Arch Pathol Lab Med; 2007 Apr; 131(4):563-70. PubMed ID: 17425385
[TBL] [Abstract][Full Text] [Related]
20. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis.
Kane D; Roth J; Frosch M; Vogl T; Bresnihan B; FitzGerald O
Arthritis Rheum; 2003 Jun; 48(6):1676-85. PubMed ID: 12794836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
